Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
Background. To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. Methods. 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washou...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/4019248 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550601062350848 |
|---|---|
| author | Xuan Du Wen Lu Zijun Lu Xinyu Shao Chunhong Hu Bimin Shi |
| author_facet | Xuan Du Wen Lu Zijun Lu Xinyu Shao Chunhong Hu Bimin Shi |
| author_sort | Xuan Du |
| collection | DOAJ |
| description | Background. To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. Methods. 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washout treatment of metformin, 6-month exenatide treatment, and 6-month glargine treatment were administrated sequentially accompanied with previous metformin. Glucolipid metabolic parameters were compared among groups. Adipose distribution was quantified with computerized tomography according to anatomy, dividing into visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), adding up to total adipose tissue (TAT). Results. The 6-month exenatide treatment dramatically ameliorated the glucose and lipid profile, improved insulin sensitivity, and mainly decreased VAT and also the ratio of VAT/SAT (RVS). The following 6-month glargine treatment increased VAT. The whole 12-month sequential treatment with exenatide and glargine added to metformin basically improved the insulin sensitivity and glucolipid control though VAT rebounded at the end, however without deteriorating the other parameters. Conclusion. Exenatide is an ideal treatment for obese type 2 diabetic patients in the aspect of adipose tissue distribution. Sequential treatment of exenatide and glargine could be an alternative for low-income patients who cannot afford GLP-1 agonist for long time. This trial is registered with ChiCTR-OOC-17013679. |
| format | Article |
| id | doaj-art-068a22ec586f4dca9c64f93517b3e58a |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-068a22ec586f4dca9c64f93517b3e58a2025-02-03T06:06:13ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/40192484019248Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin ResistanceXuan Du0Wen Lu1Zijun Lu2Xinyu Shao3Chunhong Hu4Bimin Shi5Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaBackground. To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. Methods. 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washout treatment of metformin, 6-month exenatide treatment, and 6-month glargine treatment were administrated sequentially accompanied with previous metformin. Glucolipid metabolic parameters were compared among groups. Adipose distribution was quantified with computerized tomography according to anatomy, dividing into visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), adding up to total adipose tissue (TAT). Results. The 6-month exenatide treatment dramatically ameliorated the glucose and lipid profile, improved insulin sensitivity, and mainly decreased VAT and also the ratio of VAT/SAT (RVS). The following 6-month glargine treatment increased VAT. The whole 12-month sequential treatment with exenatide and glargine added to metformin basically improved the insulin sensitivity and glucolipid control though VAT rebounded at the end, however without deteriorating the other parameters. Conclusion. Exenatide is an ideal treatment for obese type 2 diabetic patients in the aspect of adipose tissue distribution. Sequential treatment of exenatide and glargine could be an alternative for low-income patients who cannot afford GLP-1 agonist for long time. This trial is registered with ChiCTR-OOC-17013679.http://dx.doi.org/10.1155/2018/4019248 |
| spellingShingle | Xuan Du Wen Lu Zijun Lu Xinyu Shao Chunhong Hu Bimin Shi Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance Journal of Diabetes Research |
| title | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance |
| title_full | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance |
| title_fullStr | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance |
| title_full_unstemmed | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance |
| title_short | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance |
| title_sort | exenatide with metformin ameliorated visceral adiposity and insulin resistance |
| url | http://dx.doi.org/10.1155/2018/4019248 |
| work_keys_str_mv | AT xuandu exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance AT wenlu exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance AT zijunlu exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance AT xinyushao exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance AT chunhonghu exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance AT biminshi exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance |